AEON Biopharma, Inc. Contracts & Agreements
28 Contracts & Agreements
- Business Finance (14 contracts)
- Business Operations (3)
- Human Resources (9)
- Intellectual Property (2)
- Form of Promissory Note issued to Daewoong Pharmaceutical Co., Ltd (Filed With SEC on October 4, 2021)
- Amendment to Promissory Note issued to Daewoong Pharmaceutical Co., Ltd., dated May 10, 2021 (Filed With SEC on October 4, 2021)
- Amendment No. 1 to Third Amended and Restated Investors Rights Agreement (Filed With SEC on October 4, 2021)
- Form of Indemnification Agreement between the Registrant and its directors and officers (Filed With SEC on October 4, 2021)
- Form of the Registrants 2021 Equity Incentive Plan (Filed With SEC on October 4, 2021)
- Form of Stock Option Agreement under the Registrants 2021 Equity Incentive Plan (Filed With SEC on October 4, 2021)
- Form of Restricted Stock Unit Award Agreement under the Registrants 2021 Equity Incentive Plan (Filed With SEC on October 4, 2021)
- Form of the Registrants 2021 Employee Stock Purchase Plan (Filed With SEC on October 4, 2021)
- Form of Amended and Restated Employment Agreement, by and between the Registrant and Marc Forth (Filed With SEC on October 4, 2021)
- Form of Amended and Restated Employment Agreement, by and between the Registrant and Chris Carr (Filed With SEC on October 4, 2021)
- Form of the Registrants Non-Employee Director Compensation Program (Filed With SEC on October 4, 2021)
- License and Supply Agreement, dated as of December 20, 2019, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant (Filed With SEC on October 4, 2021)
- Form of Underwriting Agreement (Filed With SEC on September 17, 2021)
- Warrant to Purchase Series B Preferred Stock (Filed With SEC on September 17, 2021)
- Amended and Restated 2019 Promissory Note, effective as of June 19, 2019, issued to Dental Innovations BVBA (Filed With SEC on September 17, 2021)
- Form of 2019 Promissory Note (Filed With SEC on September 17, 2021)
- Form of Amendment No. 1 to Form of 2019 Promissory Note, dated September 30, 2020 (Filed With SEC on September 17, 2021)
- Form of Letter Agreement, dated January 8, 2020, amending 2019 Promissory Note (Filed With SEC on September 17, 2021)
- Promissory Note, dated as of January 2, 2020, issued to Strathspey Crown Holdings Group, LLC (Filed With SEC on September 17, 2021)
- Amendment No. 1 to Promissory Note, dated as of September 30, 2020, issued to Strathspey Crown Holdings Group, LLC (Filed With SEC on September 17, 2021)
- Third Amended and Restated Investors Rights Agreement, dated April 19, 2017, by and among the Registrant and the investors listed therein (Filed With SEC on September 17, 2021)
- Amended and Restated 2013 Stock Incentive Plan (Filed With SEC on September 17, 2021)
- First Amendment to Amended and Restated 2013 Stock Incentive Plan (Filed With SEC on September 17, 2021)
- Form of Stock Option Agreement under the Registrants Amended and Restated 2013 Stock Incentive Plan (Filed With SEC on September 17, 2021)
- License and Supply Agreement, dated as of December 20, 2019, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant (Filed With SEC on September 17, 2021)
- Master Intercompany Shared Services Agreement, dated as of August 19, 2019, by and between the Registrant and Strathspey Crown Limited, LLC (Filed With SEC on September 17, 2021)
- Settlement and License Agreement dated June 21, 2021 by and between the Registrant and Medytox, Inc (Filed With SEC on September 17, 2021)
- Registration Rights Agreement dated June 21, 2021 by and between the Registrant and Medytox, Inc (Filed With SEC on September 17, 2021)
